BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
April 03, 2024 04:00 ET
|
AKAMPION
Further expansion of management expertise to accelerate BellaSeno´s market entry Leipzig, Germany, April 3, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable...
MetrioPharm stellt wissenschaftlichen Beirat aus erfahrenen Immunologie- und Pädiatrie-Experten vor
March 13, 2024 06:00 ET
|
AKAMPION
Die neuen Beiräte werden ihr Fachwissen in den Bereichen Immunologie, Pathologie, Entzündungsprozesse und in MetrioPharms Hauptindikation Duchenne-Muskeldystrophie einbringenDie Beiräte haben bereits...
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
March 13, 2024 06:00 ET
|
AKAMPION
The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm's lead indication Duchenne muscular dystrophy Advisors have previously collaborated with...
BellaSeno’s 3D-printed Resorbable Scaffold Successfully Used in Critical-Size Large Segmental Radius Bone Defect at Hannover Medical School
March 05, 2024 04:00 ET
|
AKAMPION
-- Trauma patient suffered from third degree open infected fracture of its radial shaft after injury by a bullet -- Graft vascularization was achieved by embedding vascular pedicle into the scaffold ...
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
February 20, 2024 04:00 ET
|
AKAMPION
- Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria JERUSALEM, Israel, February 20, 2023 -- Omnix Medical, a...
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
February 06, 2024 04:00 ET
|
AKAMPION
- First dose level rated as safe by independent Data Safety Monitoring Board- Second dose level to be administered according to plan- THE001 designed as targeted tumor treatment independent...
MetrioPharm veröffentlicht Studiendaten, die die Wirkung einer Host-Directed Therapy in COVID-19 zeigen
January 31, 2024 05:00 ET
|
AKAMPION
Ergebnisse stammen aus der klinischen Studie CT-05 an 131 hospitalisierten Patienten mit COVID-19Die Daten zeigen, dass MetrioPharms Leitsubstanz MP1032 eine mit Remdesivir vergleichbare Wirksamkeit...
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
January 31, 2024 05:00 ET
|
AKAMPION
Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional...
New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe
January 31, 2024 04:00 ET
|
AKAMPION
New clinical trial site opened in Italy for pectus excavatum and planned in Germany for bone reconstructionCompany aims to expand EU market authorization from custom-made to off-the-shelf products and...
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
January 05, 2024 04:00 ET
|
AKAMPION
Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patientsPipeline molecule to treat T cell mediated autoimmune diseases San Diego, CA, USA, and...